1
|
da Silva JL, de Souza BSW, de Albuquerque LZ, Aleixo SB, Resende GADS, de Oliveira DGB, dos Santos EN, Nogueira-Rodrigues A, Clara RO, Gaui MDFD, Mota ACDA, de Lima VCC, Rosa DD, Munhoz RR, Morbeck IAP, Gelatti ACZ, Mathias CMDC, de Melo AC. Factors influencing COVID-19 mortality among cancer patients: A Brazilian multi-institutional study. PLoS One 2023; 18:e0295597. [PMID: 38127882 PMCID: PMC10734930 DOI: 10.1371/journal.pone.0295597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Accepted: 11/24/2023] [Indexed: 12/23/2023] Open
Abstract
PURPOSE This study aimed to describe the demographic and clinical characteristics of cancer patients with COVID-19, exploring factors associated with adverse outcomes. PATIENTS AND METHODS This retrospective cohort study methodically extracted and curated data from electronic medical records (EMRs) of numerous healthcare institutions on cancer patients diagnosed with a confirmed SARS-CoV-2 infection between May 2020 and August 2021, to identify risk factors linked to extended hospitalization and mortality. The retrieved information encompassed the patients' demographic and clinical characteristics, including the incidence of prolonged hospitalization, acute complications, and COVID-19-related mortality. RESULTS A total of 1446 cancer patients with COVID-19 were identified (mean [Standard deviation] age, 59.2 [14.3] years). Most patients were female (913 [63.1%]), non-white (646 [44.7%]), with non-metastatic (818 [56.6%]) solid tumors (1318 [91.1%]), and undergoing chemotherapy (647 [44.7%]). The rate of extended hospitalization due to COVID-19 was 46% (n = 665), which was significantly impacted by age (p = 0.012), sex (p = 0.003), race and ethnicity (p = 0.049), the presence of two or more comorbidities (p = 0.006), hematologic malignancies (p = 0.013), metastatic disease (p = 0.002), and a performance status ≥ 2 (p = 0.001). The COVID-19-related mortality rate was 18.9% (n = 273), and metastatic disease (<0.001), performance status ≥2 (<0.001), extended hospitalization (p = 0.028), renal failure (p = 0.029), respiratory failure (p < 0.001), sepsis (p = 0.004), and shock (p = 0.040) significantly and negatively influenced survival. CONCLUSION The rate of extended hospitalization and COVID-19-specific death in cancer patients was notably high and could be influenced by comorbidities, cancer treatment status, and clinical fragility. These observations may aid in developing risk counseling strategies regarding COVID-19 in individuals diagnosed with cancer.
Collapse
Affiliation(s)
- Jessé Lopes da Silva
- Division of Clinical Research and Technological Development, Brazilian National Cancer Institute, Rio de Janeiro, Rio de Janeiro, Brazil
- Department of Clinical Oncology, Galeao Air Force Hospital, Rio de Janeiro, Rio de Janeiro, Brazil
| | | | - Lucas Zanetti de Albuquerque
- Division of Clinical Research and Technological Development, Brazilian National Cancer Institute, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Sabina Bandeira Aleixo
- Department of Clinical Oncology, Evangelical Hospital of Cachoeiro de Itapemirim, Cachoeiro de Itapemirim, Espírito Santo, Brazil
| | | | | | | | - Angélica Nogueira-Rodrigues
- Department of General Medicine UFMG, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
- Brazilian Society of Clinical Oncology, São Paulo, São Paulo, Brazil
| | | | | | | | | | - Daniela Dornelles Rosa
- Brazilian Society of Clinical Oncology, São Paulo, São Paulo, Brazil
- Department of Clinical Oncology, Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil
| | | | | | - Ana Caroline Zimmer Gelatti
- Oncoclinicas Group of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
- Brazilian Group of Thoracic Tumors, Porto Alegre, Rio Grande do Sul, Brazil
| | | | - Andréia Cristina de Melo
- Division of Clinical Research and Technological Development, Brazilian National Cancer Institute, Rio de Janeiro, Rio de Janeiro, Brazil
| |
Collapse
|
2
|
Mangone L, Marinelli F, Bisceglia I, Filice A, De Leonibus L, Rapicetta C, Paci M. The Influence of COVID-19 on New Lung Cancer Diagnoses, by Stage and Treatment, in Northern Italy. BIOLOGY 2023; 12:biology12030390. [PMID: 36979081 PMCID: PMC10045495 DOI: 10.3390/biology12030390] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Revised: 02/20/2023] [Accepted: 02/24/2023] [Indexed: 03/05/2023]
Abstract
The COVID-19 pandemic has had a significant impact on new cancer diagnoses. This study aims to evaluate the implications of the lockdown period on new lung cancer diagnoses in northern Italy. We compared 2020 with 2019 cancer registry data, reporting the variations by age, stage, and treatments. In 2020, 303 lung cancer cases were registered, 21 fewer than in 2019. Cases fell in men (−31 patients, 9.6%) but not in women (+10 patients, +3.1%). A significant drop in stage I from 19.8% to 12.9% (p < 0.05) and an increase in stage III (12.7% vs. 19.1%; p < 0.05) was observed. Histological confirmation dropped (70.1% vs. 60.1%; p < 0.05) while cytology increased (12% vs. 20.8%; p < 0.01). Surgery declined (28.7% vs. 21.5%; p < 0.05) but increased in stage III (19.5% vs. 25.9%; p = 0.46), while chemotherapy increased (17.6% vs. 34.3%; p < 0.01) for all stages. During the pandemic, new lung cancer diagnoses dropped only in men. The reorganization of health services has ensured a decrease in surgical interventions (due to the unavailability of operating rooms) counterbalanced by an increase in chemotherapy.
Collapse
Affiliation(s)
- Lucia Mangone
- Epidemiology Unit, Azienda Unità Sanitaria Locale–IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy
- Correspondence:
| | - Francesco Marinelli
- Epidemiology Unit, Azienda Unità Sanitaria Locale–IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy
| | - Isabella Bisceglia
- Epidemiology Unit, Azienda Unità Sanitaria Locale–IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy
| | - Angelina Filice
- Nuclear Medicine Unit, Azienda Unità Sanitaria Locale–IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy
| | - Lisa De Leonibus
- Thoracic Surgery Unit, Azienda Unità Sanitaria Locale–IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy
| | - Cristian Rapicetta
- Thoracic Surgery Unit, Azienda Unità Sanitaria Locale–IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy
| | - Massimiliano Paci
- Thoracic Surgery Unit, Azienda Unità Sanitaria Locale–IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy
| |
Collapse
|
3
|
van Vliet ED, Eijkelboom AH, van Giessen A, Siesling S, de Wit GA. Physical and mental health outcomes of COVID-19 induced delay in oncological care: A systematic review. Front Oncol 2023; 13:998940. [PMID: 36776332 PMCID: PMC9911660 DOI: 10.3389/fonc.2023.998940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Accepted: 01/16/2023] [Indexed: 01/29/2023] Open
Abstract
Background During the COVID-19 pandemic cancer patients might have experienced delays in screening, diagnosis and/or treatment. A systematic review was conducted to give an overview of the effects of COVID-19 induced delays in oncological care on the physical and mental health outcomes of cancer patients. Methods MEDLINE and EMBASE databases were searched for articles on the effects of COVID-19 induced delays on physical and mental health outcomes. Results Out of 1333 papers, eighteen observational, and twelve modelling studies were included. In approximately half of the studies, tumor stage distribution differed during the pandemic compared to before the pandemic. Modelling studies predicted that the estimated increase in the number of deaths ranged from -0.04 to 30%, and the estimated reduction in survival ranged from 0.4 to 35%. Varying results on the impact on mental health, e.g. anxiety and depression, were seen. Conclusions Due to large methodological discrepancies between the studies and the varying results, the effect of COVID-19 induced delays on the physical and mental health outcomes of cancer patients remains uncertain. While modelling studies estimated an increase in mortality, observational studies suggest that mortality might not increase to a large extent. More longitudinal observational data from the pandemic period is needed for more conclusive results.
Collapse
Affiliation(s)
- Ella D. van Vliet
- Center for Health Protection, National Institute of Public Health and the Environment (RIVM), Bilthoven, Netherlands,*Correspondence: Ella D. van Vliet,
| | - Anouk H. Eijkelboom
- Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, Netherlands,Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, Netherlands
| | - Anoukh van Giessen
- Center for Nutrition, Prevention and Healthcare, National Institute of Public Health and the Environment (RIVM), Bilthoven, Netherlands
| | - Sabine Siesling
- Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, Netherlands,Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, Netherlands
| | - G. Ardine de Wit
- Center for Nutrition, Prevention and Healthcare, National Institute of Public Health and the Environment (RIVM), Bilthoven, Netherlands,Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam & Amsterdam Health Research Institute, Amsterdam, Netherlands
| |
Collapse
|
4
|
Sobreira da Silva MJ, Serpa Osorio-de-Castro CG, Paes RD, Negrete CL, Eugênio E, Moraes EL, Livinalli A. Potential interactions between antineoplastic agents and medicines used to treat Covid-19. J Oncol Pharm Pract 2022; 28:1737-1748. [PMID: 34637360 PMCID: PMC9619075 DOI: 10.1177/10781552211040494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
INTRODUCTION Cancer patients with Covid-19 are exposed to treatment combinations that can potentially result in interactions that adversely affect patient outcomes. This study aimed to identify potential drug-drug interactions between antineoplastic agents and medicines used to treat Covid-19. METHODS We conducted a search for potential interactions between 201 antineoplastic agents and 26 medicines used to treat Covid-19 on the Lexicomp® and Micromedex® databases. The following data were extracted: interaction severity ("major" and "contraindicated") and interaction effects (pharmacokinetic and pharmacodynamic). We also sought to identify the therapeutic indication of the antineoplastic drugs involved in the potential drug-drug interactions. RESULTS A total of 388 "major" or "contraindicated" drug-drug interactions were detected. Eight drugs or combinations (baricitinib, lopinavir/ritonavir, atazanavir, darunavir, azithromycin, chloroquine, hydroxychloroquine, and sirolimus) accounted for 91.5% of these interactions. The class of antineoplastic agents with the greatest potential for interaction was tyrosine kinase inhibitors (accounting for 46.4% of all interactions). The findings show that atazanavir, baricitinib, and lopinavir/ritonavir can affect the treatment of all common types of cancer. The most common pharmacokinetic effect of the potential drug-drug interactions was increased plasma concentration of the antineoplastic medicine (39.4%). CONCLUSIONS Covid-19 is a recent disease and pharmacological interventions are undergoing constant modification. This study identified a considerable number of potential drug-drug interactions. In view of the vulnerability of patients with cancer, it is vital that health professionals carefully assess the risks and benefits of drug combinations.
Collapse
Affiliation(s)
- Mario Jorge Sobreira da Silva
- National Cancer Institute of
Brazil, Brazil,Mario Jorge Sobreira da Silva, Rua Marquês
de Pombal, 125, 3° andar – Centro, Rio de Janeiro, RJ 20230-240, Brazil.
| | | | | | | | | | | | | |
Collapse
|
5
|
The Impact of COVID-19 Infection in Cancer 2020-2021. Cancers (Basel) 2022; 14:cancers14235895. [PMID: 36497376 PMCID: PMC9738891 DOI: 10.3390/cancers14235895] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Accepted: 11/25/2022] [Indexed: 12/03/2022] Open
Abstract
This Editorial summarizes the findings of the articles submitted in 2020 and 2021 to the Special Issue "The Impact of COVID-19 in Cancer".
Collapse
|
6
|
The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center. Curr Oncol 2022; 29:8677-8685. [PMID: 36421337 PMCID: PMC9689557 DOI: 10.3390/curroncol29110684] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Revised: 11/08/2022] [Accepted: 11/11/2022] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND We have recently reported a 35% drop in new lung cancer diagnoses and a 64% drop in lung cancer surgeries during the first year of the pandemic. METHODS The target population was divided into three cohorts: pre-COVID-19 (2019), first year of COVID-19 (2020), and second year of COVID-19 (2021). RESULTS The number of new lung cancer diagnoses during the second year of the pandemic increased by 75%, with more than 50% being in the advanced/metastatic stage. There was a significant increase in cases with multiple extrathoracic sites of metastases during the pandemic. During the first year of the pandemic, significantly more patients were treated with radiosurgery compared to the pre-COVID-19 year. During the second year, the number of radiosurgery and surgical cases returned to pre-COVID-19 levels. No significant changes were observed in systemic chemotherapy and targeted therapy. No statistical difference was identified in the mean wait time for diagnosis and treatment during the three years of observation. However, the wait time for surgery was prolonged compared to the pre-COVID-19 cohort. CONCLUSIONS The significant drop in new diagnoses of lung cancer during the first year of the pandemic was followed by an almost two-fold increase in the second year, with the increased rate of metastatic disease with multiple extra-thoracic site metastases. Limited access to surgery resulted in the more frequent use of radiosurgery.
Collapse
|
7
|
Bogaert B, Buisson V, Kozlakidis Z, Saintigny P. Organisation of cancer care in troubling times: A scoping review of expert guidelines and their implementation during the COVID-19 pandemic. Crit Rev Oncol Hematol 2022; 173:103656. [PMID: 35337970 PMCID: PMC8942466 DOI: 10.1016/j.critrevonc.2022.103656] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2021] [Revised: 03/15/2022] [Accepted: 03/18/2022] [Indexed: 12/12/2022] Open
Abstract
This scoping review mapped the main themes in existing expert guidelines for cancer care issued during the COVID-19 crisis from the period of March 2020-August 2021. The guidelines published during the research period principally relate to the first two waves in Europe and until the beginning of the vaccination campaign. They elaborated recommendations for cancer care reorganisation, in particular triage and quality of care issues. The article highlights the ethical, epistemological, as well as practical reasons that guidelines were not always followed to provide some lessons learned for future crises to enable better guideline development processes. We also elaborate early evidence on the impact of triage decisions and different perspectives on cancer care reorganisation from ethics and social science literature.
Collapse
Affiliation(s)
- Brenda Bogaert
- Department of Social Sciences and Humanities, Centre Léon Bérard, Lyon, France.
| | - Victoria Buisson
- Department of Social Sciences and Humanities, Centre Léon Bérard, Lyon, France.
| | - Zizis Kozlakidis
- International Agency for Research on Cancer, World Health Organization, Lyon, France.
| | - Pierre Saintigny
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Univ Lyon, Claude Bernard Lyon 1 University, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France.
| |
Collapse
|
8
|
Joerger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt AM, Cantoni N, Caspar CB, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz JD, Kopp C, Hayoz S, Stathis A, von Moos R. Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). Cancers (Basel) 2022; 14:2191. [PMID: 35565320 PMCID: PMC9104745 DOI: 10.3390/cancers14092191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2022] [Revised: 04/24/2022] [Accepted: 04/25/2022] [Indexed: 02/04/2023] Open
Abstract
Purpose: These are the final results of a national registry on cancer patients with COVID-19 in Switzerland. Methods: We collected data on symptomatic COVID-19-infected cancer patients from 23 Swiss sites over a one-year period starting on 1 March 2020. The main objective was to assess the outcome (i.e., mortality, rate of hospitalization, ICU admission) of COVID-19 infection in cancer patients; the main secondary objective was to define prognostic factors. Results: From 455 patients included, 205 patients (45%) had non-curative disease, 241 patients (53%) were hospitalized for COVID-19, 213 (47%) required oxygen, 43 (9%) invasive ventilation and 62 (14%) were admitted to the ICU. Death from COVID-19 infection occurred in 98 patients, resulting in a mortality rate of 21.5%. Age ≥65 years versus <65 years (OR 3.14, p = 0.003), non-curative versus curative disease (OR 2.42, p = 0.012), ICU admission (OR 4.45, p < 0.001) and oxygen requirement (OR 20.28, p < 0.001) were independently associated with increased mortality. Conclusions: We confirmed high COVID-19 severity and mortality in real-world cancer patients during the first and second wave of the pandemic in a country with a decentralized, high-quality, universal-access health care system. COVID-19-associated mortality was particularly high for those of older age in a non-curative disease setting, requiring oxygen or ICU care.
Collapse
Affiliation(s)
- Markus Joerger
- Department of Oncology, Cantonal Hospital, 9007 St. Gallen, Switzerland
| | - Yannis Metaxas
- Department of Medical Oncology, Cantonal Hospital, 8596 Muensterlingen, Switzerland;
| | - Khalil Zaman
- Breast Center, Department of Medical Oncology, University Hospital, 1011 Lausanne, Switzerland;
| | - Olivier Michielin
- Department of Medical Oncology, University Hospital, 1011 Lausanne, Switzerland;
| | - Nicolas Mach
- Department of Medical Oncology, University Hospital, 1205 Geneva, Switzerland;
| | - Adrienne Bettini
- Department of Medical Oncology, HFR Fribourg-Hôpital Cantonal, 1752 Fribourg, Switzerland;
| | - Andreas M. Schmitt
- Department of Medical Oncology, University Hospital, 4031 Basel, Switzerland;
| | - Nathan Cantoni
- Oncology, Hematology and Transfusion Medicine, Cantonal Hospital, 5001 Aarau, Switzerland;
| | - Clemens B. Caspar
- Division of Hematology and Oncology, Cantonal Hospital, 5404 Baden, Switzerland;
| | - Sonja Stettler
- Division of Medical Oncology, Lucerne Cantonal Hospital, 6000 Lucerne, Switzerland;
| | | | - Miklos Pless
- Division of Medical Oncology and Hematology, Cantonal Hospital, 8400 Winterthur, Switzerland;
| | - Christian Britschgi
- Department of Medical Oncology and Hematology, University Hospital, 8091 Zurich, Switzerland;
| | - Christoph Renner
- Department of Medical Oncology, Oncological Center Zurich, 8038 Zurich, Switzerland;
| | - Dieter Koeberle
- Department of Oncology, Claraspital, 4058 Basel, Switzerland;
| | - Jessica D. Schulz
- SAKK Coordinating Center, 3008 Bern, Switzerland; (J.D.S.); (C.K.); (S.H.)
| | - Christoph Kopp
- SAKK Coordinating Center, 3008 Bern, Switzerland; (J.D.S.); (C.K.); (S.H.)
| | - Stefanie Hayoz
- SAKK Coordinating Center, 3008 Bern, Switzerland; (J.D.S.); (C.K.); (S.H.)
| | - Anastasios Stathis
- Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland;
| | - Roger von Moos
- Department of Medical Oncology/Hematology, Cantonal Hospital Graubuenden, 7000 Chur, Switzerland;
| |
Collapse
|
9
|
Adamakidou T, Charalambous A. How did SARS-CoV-2 changed the landscape in cancer care. Eur J Oncol Nurs 2022; 57:102118. [PMID: 35307319 PMCID: PMC8883722 DOI: 10.1016/j.ejon.2022.102118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 02/27/2022] [Indexed: 11/27/2022]
Affiliation(s)
| | - Andreas Charalambous
- Nursing Department, Cyprus University of Technology, Nursing Department, University of Turku, Finland.
| |
Collapse
|
10
|
Kasymjanova G, Anwar A, Cohen V, Sultanem K, Pepe C, Sakr L, Friedmann J, Agulnik JS. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Center: A Retrospective Chart Review. Curr Oncol 2021; 28:4247-4255. [PMID: 34898542 PMCID: PMC8544580 DOI: 10.3390/curroncol28060360] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Revised: 10/05/2021] [Accepted: 10/18/2021] [Indexed: 02/07/2023] Open
Abstract
The large burden of COVID-19 on health care systems worldwide has raised concerns among medical oncologists about the impact of COVID-19 on the diagnosis and treatment of lung cancer patients. In this retrospective cohort study, we investigated the impact of COVID-19 on lung cancer diagnosis and treatment before and during the COVID-19 era. New lung cancer diagnoses decreased by 34.7% during the pandemic with slightly more advanced stages of disease, there was a significant increase in the utilization of radiosurgery as the first definitive treatment, and a decrease in both systemic treatment as well as surgery compared to the pre-COVID-19 era. There was no significant delay in starting chemotherapy and radiation treatment during the pandemic compared to pre-COVID-19 time. However, we observed a delay to lung cancer surgery during the pandemic time. COVID-19 seems to have had a major impact at our lung cancer center on the diagnoses and treatment patterns of lung cancer patients. Many oncologists fear that they will see an increase in newly diagnosed lung cancer patients in the coming year. This study is still ongoing and further data will be collected and analyzed to better understand the total impact of the COVID-19 pandemic on our lung cancer patient population.
Collapse
Affiliation(s)
- Goulnar Kasymjanova
- Peter Brojde Lung Cancer Center, Jewish General Hospital, McGill University, Montreal, QC H3T1E2, Canada; (C.P.); (L.S.); (J.S.A.)
- Correspondence:
| | - Aksa Anwar
- Department of Oncology, McGill University, Montreal, QC H3T1E2, Canada;
| | - Victor Cohen
- Segal Cancer Centre, Medical Oncology, Jewish General Hospital, McGill University, Montreal, QC H3T1E2, Canada; (V.C.); (J.F.)
| | - Khalil Sultanem
- Segal Cancer Centre, Radiation Oncology, Jewish General Hospital, McGill University, Montreal, QC H3T1E2, Canada;
| | - Carmela Pepe
- Peter Brojde Lung Cancer Center, Jewish General Hospital, McGill University, Montreal, QC H3T1E2, Canada; (C.P.); (L.S.); (J.S.A.)
| | - Lama Sakr
- Peter Brojde Lung Cancer Center, Jewish General Hospital, McGill University, Montreal, QC H3T1E2, Canada; (C.P.); (L.S.); (J.S.A.)
| | - Jennifer Friedmann
- Segal Cancer Centre, Medical Oncology, Jewish General Hospital, McGill University, Montreal, QC H3T1E2, Canada; (V.C.); (J.F.)
| | - Jason S. Agulnik
- Peter Brojde Lung Cancer Center, Jewish General Hospital, McGill University, Montreal, QC H3T1E2, Canada; (C.P.); (L.S.); (J.S.A.)
| |
Collapse
|
11
|
Indini A, Costa S, Ierardi AM, Rijavec E, Passoni E, Grossi F. COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report. Melanoma Res 2021; 31:490-493. [PMID: 34433198 PMCID: PMC8423031 DOI: 10.1097/cmr.0000000000000768] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Accepted: 07/03/2021] [Indexed: 11/26/2022]
Abstract
COVID-19 vaccination has been rapidly implemented among patients with cancer. We present the case of a patient with high-risk resected cutaneous melanoma, who was a candidate for adjuvant treatment, with postsurgery 18-fluorodeoxyglucose (FDG) PET/computed tomography (CT) scan showing positive axillary lymph nodes after COVID-19 vaccination. This report presents a 50-year-old man with a history of stage IIA cutaneous melanoma. During follow-up, the patient experienced subcutaneous and lymph-node disease progression, documented with 18FDG PET/CT scan. The patient underwent laparoscopic left para-aortic lymphadenectomy and excision of subcutaneous lesion. Histologic examination showed presence of melanoma metastases in 2 lymph nodes out of total 17 excised and neoplastic emboli to the subcutaneous tissue. In view of starting adjuvant nivolumab, the patient underwent CT scan restaging, with evidence of suspect centimetric periaortic and paracaval lymph nodes, which were deemed worthy of 18FDG PET investigation. The 18FDG PET/CT was negative for abdominal hypercaptation, but showed left axillary pathologic lymph nodes. The medical history of the patient revealed that he had received intramuscular Moderna COVID-19 mRNA vaccine in the left deltoid, one week before 18FDG PET examination. Since the patient's clinical examination was negative and suspecting postvaccination false-positive adenopathy, bilateral axillary ultrasound was performed, excluding the presence of pathologic lymph nodes. The patient has started adjuvant treatment with nivolumab, which is currently ongoing. This case demonstrates unexpected findings in response to COVID-19 vaccination in a patient with melanoma. In this specific case, the detection of 18FDG PET hypercaptation could significantly change the patient's management. With growing evidence about the pattern and occurrence of adenopathies after mRNA COVID-19 vaccination, recommendations for scheduling and interpretation of 18FDG PET/CT scans among cancer patients will be implemented, in order to reduce equivocal findings and improve outcomes.
Collapse
Affiliation(s)
| | | | | | | | - Emanuela Passoni
- Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano
| | - Francesco Grossi
- Unit of Medical Oncology, Department of Medicine and Surgery, University of Insubria, ASST dei Sette Laghi, Varese, Italy
| |
Collapse
|
12
|
Ashbury FD, Thompson K, Williams C, Williams K. Challenges adopting next-generation sequencing in community oncology practice. Curr Opin Oncol 2021; 33:507-512. [PMID: 34183492 DOI: 10.1097/cco.0000000000000764] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
PURPOSE OF REVIEW We are in an exhilarating time in which innovations exist to help reduce the impact of cancer for individuals, practitioners and society. Innovative tools in cancer genomics can optimize decision-making concerning appropriate drugs (alone or in combination) to cure or prolong life. The genomic characterization of tumours can also give direction to the development of novel drugs. Next-generation tumour sequencing is increasingly becoming an essential part of clinical decision-making, and, as such, will require appropriate coordination for effective adoption and delivery. RECENT FINDINGS There are several challenges that will need to be addressed if we are to facilitate cancer genomics as part of routine community oncology practice. Recent research into this novel testing paradigm has demonstrated the barriers are at the individual level, while others are at the institution and societal levels. SUMMARY This article, based on the authors' experience in community oncology practice and summary of literature, describes these challenges so strategies can be developed to address these challenges to improve patient outcomes.
Collapse
Affiliation(s)
- Fredrick D Ashbury
- VieCure, Denver, Colorado, USA
- Department of Oncology, University of Calgary, Calgary, Alberta
- Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - Keith Thompson
- VieCure, Denver, Colorado, USA
- Faculty of Medicine, University of Alabama, Birmingham
- Montgomery Cancer Center, Montgomery, Alabama
| | - Casey Williams
- University of South Dakota
- Avera Cancer Institute, Sioux Falls, South Dakota, USA
| | | |
Collapse
|
13
|
Abubakar L, Salemcity AJ, Abass OK, Olajuyin AM. The impacts of COVID-19 on environmental sustainability: A brief study in world context. BIORESOURCE TECHNOLOGY REPORTS 2021; 15:100713. [PMID: 36569977 PMCID: PMC9758479 DOI: 10.1016/j.biteb.2021.100713] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Revised: 04/25/2021] [Accepted: 04/25/2021] [Indexed: 12/27/2022]
Abstract
The novel outbreak of Coronavirus disease 19 (COVID-19) and the ensuing global pandemic in 2020, has brought with it a number of unprecedented side effects. This resulted in a number of measures, including state-mandated lockdowns, as well as restrictions to economic and social activity. The direct effects of these measures were felt in the economy, as well as in key institutions within society; however, there were also indirect results from these changes. This review article focuses on these indirect effects, towards sustainable environment. It points to the fact that the net effect has been positive; in terms of reduction in greenhouse emissions, oil exploration activities, and pollution. By extension, at-risk ecosystems have been given improved environmental quality. Taken together, the article traces the progression of the virus and ensuing pandemic, in order to better understand how the environment was sustained.
Collapse
Affiliation(s)
- Laila Abubakar
- Department of Politics and International Studies, American University of Nigeria, 98 Lamido Zubairu way Yola Bypass P.M.B.2250, Yola, Adamawa, Nigeria
| | | | - Olusegun K. Abass
- School of Civil and Environmental Engineering, Nanyang Technological University, Singapore 639798, Singapore
| | - Ayobami Matthew Olajuyin
- Department of Natural and Environmental Sciences, American University of Nigeria, 98 Lamido Zubairu way Yola Bypass P.M.B.2250, Yola, Adamawa, Nigeria,Corresponding author
| |
Collapse
|
14
|
Soriano EC, Perndorfer C, Otto AK, Fenech AL, Siegel SD, Dickson-Witmer D, Clements L, Laurenceau JP. Psychosocial Impact of Cancer Care Disruptions in Women With Breast Cancer During the COVID-19 Pandemic. Front Psychol 2021; 12:662339. [PMID: 34194367 PMCID: PMC8236578 DOI: 10.3389/fpsyg.2021.662339] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Accepted: 04/28/2021] [Indexed: 01/11/2023] Open
Abstract
Background: The COVID-19 pandemic caused significant disruptions in cancer care, and preliminary research suggests that these disruptions are associated with increased levels of psychosocial distress among cancer survivors. The purpose of this study was to offer a descriptive report of the psychosocial functioning, perceived risk and fear of cancer progression, and COVID-19 pandemic impact and experiences in a unique, high-risk patient cohort: breast cancer survivors whose cancer treatment was delayed and/or changed due to the COVID-19 pandemic. Methods: This cross-sectional study included 50 women with dual carcinoma in situ, lobular carcinoma in situ, or invasive breast cancer whose cancer surgery was postponed due to the pandemic. As they awaited delayed surgery or shortly after they received delayed surgery, participants completed questionnaires on psychosocial functioning (depression, anxiety, sleep, and quality of life), their perceived risk and fear of cancer progression, patient-provider communication about disruptions in their care, personal impact of the pandemic, worry/threat about COVID-19, and COVID-19 symptoms/diagnoses. Descriptive statistics and bivariate correlations were computed among continuous study variables. Independent samples t-tests explored group differences in psychosocial functioning between survivors who were still awaiting delayed surgery and those who had recently received it. Results: Overall, the sample denied that the pandemic seriously negatively impacted their finances or resource access and reported low-to-moderate levels of psychosocial distress and fear about COVID-19. Twenty-six percent had clinically significant levels of fear of cancer progression, with levels comparable to other recent work. About a third were still awaiting delayed cancer surgery and this group reported lower satisfaction with communication from oncology providers but overall did not seem to report more psychosocial difficulties than those who already had surgery. Conclusion: Shortly before or after primary breast cancer surgery that was delayed due to the COVID-19 pandemic, this sample of survivors appears to be generally managing well psychosocially. However, many psychosocial difficulties (e.g., fear of cancer recurrence/progression) typically have an onset after the completion of treatment, therefore, research should continue to follow this cohort of cancer survivors as the pandemic's direct impact on their care likely increases their risk for these difficulties later in survivorship.
Collapse
Affiliation(s)
- Emily C. Soriano
- Department of Psychological and Brain Sciences, University of Delaware, Newark, DE, United States
| | - Christine Perndorfer
- Department of Psychological and Brain Sciences, University of Delaware, Newark, DE, United States
| | - Amy K. Otto
- Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, United States
| | - Alyssa L. Fenech
- Department of Psychological and Brain Sciences, University of Delaware, Newark, DE, United States
| | - Scott D. Siegel
- Christiana Care Health System, Helen F. Graham Cancer Center and Research Institute, Newark, DE, United States
| | - Diana Dickson-Witmer
- Christiana Care Health System, Helen F. Graham Cancer Center and Research Institute, Newark, DE, United States
| | - Lydia Clements
- Christiana Care Health System, Helen F. Graham Cancer Center and Research Institute, Newark, DE, United States
| | - Jean-Philippe Laurenceau
- Department of Psychological and Brain Sciences, University of Delaware, Newark, DE, United States
| |
Collapse
|
15
|
Cocco D, Valente SA. Sentinel Lymph Node Mapping and Biopsy in Breast Cancer Patients During the COVID-19 Pandemic. Ann Surg Oncol 2021; 28:4056-4057. [PMID: 33432488 PMCID: PMC7799421 DOI: 10.1245/s10434-020-09554-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2020] [Accepted: 12/10/2020] [Indexed: 12/29/2022]
Affiliation(s)
- Daniela Cocco
- Breast Services, Cleveland Clinic Foundation, Cleveland, OH, USA.
| | | |
Collapse
|
16
|
Murakami N, Nakamura S, Kashihara T, Inaba K, Kaneda T, Takahashi K, Okuma K, Igaki H, Itami J. Increased number of prostate cancer patients selecting high dose-rate interstitial brachytherapy during the COVID-19 pandemic. Radiother Oncol 2021; 154:274-275. [PMID: 33227353 PMCID: PMC7679657 DOI: 10.1016/j.radonc.2020.11.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2020] [Accepted: 11/13/2020] [Indexed: 02/08/2023]
Affiliation(s)
- Naoya Murakami
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
| | - Satoshi Nakamura
- Department of Medical Physics, National Cancer Center Hospital, Tokyo, Japan
| | - Tairo Kashihara
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Koji Inaba
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Tomoya Kaneda
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Kana Takahashi
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Kae Okuma
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Hiroshi Igaki
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Jun Itami
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
| |
Collapse
|
17
|
Shen Y, Guo D, Long F, Mateos LA, Ding H, Xiu Z, Hellman RB, King A, Chen S, Zhang C, Tan H. Robots Under COVID-19 Pandemic: A Comprehensive Survey. IEEE ACCESS : PRACTICAL INNOVATIONS, OPEN SOLUTIONS 2020; 9:1590-1615. [PMID: 34976569 PMCID: PMC8675561 DOI: 10.1109/access.2020.3045792] [Citation(s) in RCA: 45] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Accepted: 12/08/2020] [Indexed: 05/04/2023]
Abstract
As a result of the difficulties brought by COVID-19 and its associated lockdowns, many individuals and companies have turned to robots in order to overcome the challenges of the pandemic. Compared with traditional human labor, robotic and autonomous systems have advantages such as an intrinsic immunity to the virus and an inability for human-robot-human spread of any disease-causing pathogens, though there are still many technical hurdles for the robotics industry to overcome. This survey comprehensively reviews over 200 reports covering robotic systems which have emerged or have been repurposed during the past several months, to provide insights to both academia and industry. In each chapter, we cover both the advantages and the challenges for each robot, finding that robotics systems are overall apt solutions for dealing with many of the problems brought on by COVID-19, including: diagnosis, screening, disinfection, surgery, telehealth, care, logistics, manufacturing and broader interpersonal problems unique to the lockdowns of the pandemic. By discussing the potential new robot capabilities and fields they applied to, we expect the robotics industry to take a leap forward due to this unexpected pandemic.
Collapse
Affiliation(s)
- Yang Shen
- UBTECH North America Research and Development CenterPasadenaCA91101USA
| | - Dejun Guo
- UBTECH North America Research and Development CenterPasadenaCA91101USA
| | - Fei Long
- UBTECH North America Research and Development CenterPasadenaCA91101USA
| | - Luis A. Mateos
- UBTECH North America Research and Development CenterPasadenaCA91101USA
| | - Houzhu Ding
- UBTECH North America Research and Development CenterPasadenaCA91101USA
| | - Zhen Xiu
- UBTECH North America Research and Development CenterPasadenaCA91101USA
| | | | - Adam King
- UBTECH North America Research and Development CenterPasadenaCA91101USA
| | - Shixun Chen
- UBTECH North America Research and Development CenterPasadenaCA91101USA
| | - Chengkun Zhang
- UBTECH North America Research and Development CenterPasadenaCA91101USA
| | - Huan Tan
- UBTECH North America Research and Development CenterPasadenaCA91101USA
| |
Collapse
|